US · Healthcare · Diagnostics & Research
EPS came in at -0.28 against a street estimate of -0.05 — a miss of 465.7%.
Analysts rate GeneDx Holdings Corp. a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $81.78.
| Fund | Stake |
|---|---|
| Corvex Management LP | 10.87% |
| Casdin Capital, LLC | 10.13% |
| BlackRock Inc | 5.22% |
| Westfield Capital Management Company, L.P. | 4.61% |
| The Goldman Sachs Group Inc | 4.50% |
| ARK Investment Management LLC | 4.46% |
| Vanguard Capital Management, LLC | 2.89% |
| William Blair Investment Management, LLC | 2.61% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-23 |
| Board / officer change · Q2 2026 | 2026-06-16 |
| Quarterly report · Q1 2026 | 2026-05-04 |
| Results announced · Q2 2026 | 2026-05-04 |
| Proxy statement · Q4 2025 | 2026-04-30 |
| Material agreement · Q1 2026 | 2026-03-02 |
| Annual report FY2025 | 2026-02-23 |
| Quarterly report · Q3 2025 | 2025-10-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for GeneDx Holdings Corp. — free to start.
Google PlayApp StoreData updated 2026-08-05.